Back to screener
Syngene International Limited

Syngene International Limited

SYNGENENSEBSE 539268· INE398R01022Website
₹369.05
▼ 11.15 (-2.93%) today
Latest quote · Yahoo Finance
Market Cap
₹14.85K Cr
P/E (TTM)
67.1
P/B
3.1
Book Value
₹120.41
ROE
4.6%
Div Yield
0.34%
D/E
0.09
EPS (TTM)
₹5.50
52W High
₹678.95
52W Low
₹366.65
Sales Growth
-15.80%
Profit Growth
Day High
₹384.00
Day Low
₹366.65
Volume
24,98,133
Fundamentals refreshed 18 hr ago · Statements just now · Source: Yahoo Finance

Quick Take

  • • Trading at 67.1× trailing earnings (34.6× forward)
  • • Moderate ROE at 4.6%
  • • Low leverage (D/E 0.09)
  • • Modest dividend yield of 0.34%
  • • Operating margin 3.9% · Net margin 6.1%
  • • Profit growth YoY · Beta 0.08
Employees: 6,692

Latest quarter · Jun 2026

₹ CrJun 2026QoQYoY
Revenue736-28.96%-27.70%
Operating Profit103-67.81%-71.55%
Net Profit-9-106.08%-104.92%
EPS (₹)-0.22-105.99%-104.82%
OPM 13.9% · Net margin -1.2% · prev quarter OPM 30.8%

Shareholding Pattern

Numbers in percentages · Source: NSE
Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters▼0.0954.72%52.74%52.74%52.68%52.68%52.68%52.68%52.59%
FIIs▼2.0820.72%20.64%19.47%16.50%16.31%14.96%13.90%11.82%
DIIs▲1.5817.48%19.53%21.50%24.05%24.62%25.84%26.44%28.02%
Government0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public▲0.456.74%6.80%6.00%6.45%6.08%6.22%6.69%7.14%
No. of Shareholders1,07,3371,28,8051,25,0891,42,3091,36,0601,31,7491,35,6041,42,276

* N

Who is buying / selling · last 12 months (NSE)
DatePartyTypeSideQtyPrice
30 Apr 26Microcurves Trading Private LimitedBulk dealSELL27,66,287₹482.02
30 Apr 26Microcurves Trading Private LimitedBulk dealBUY27,66,287₹481.90
30 Apr 26Nk Securities Research Private LimitedBulk dealSELL21,60,599₹486.62
30 Apr 26Nk Securities Research Private LimitedBulk dealBUY21,60,599₹486.40

About the company

From latest AR & concall
Reading the latest annual report and earnings call… (1–3 min on first visit)

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Lalbaugcha Raja
॥ श्री गणेशाय नमः ॥

गणपती बाप्पा मोरया

Happy Ganesh Chaturthi

वक्रतुण्ड महाकाय सूर्यकोटि समप्रभ ।
निर्विघ्नं कुरु मे देव सर्वकार्येषु सर्वदा ॥

May Lalbaugcha Raja remove every obstacle from your investing journey.
— Team Sankhyas 🧿